Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
25%(1 trials)

Phase Distribution

Ph not_applicable
4
67%
Ph phase_4
2
33%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 42 (33.3%)
N/A4 (66.7%)

Trials by Status

withdrawn117%
completed467%
active_not_recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_4

Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

NCT06625047
active_not_recruitingnot_applicable

Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery

NCT05203627
completedphase_4

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

NCT05108805
completednot_applicable

Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation

NCT03189212
completednot_applicable

Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic

NCT04652674
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06625047Phase 4

Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

Completed
NCT05203627Not Applicable

Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery

Active Not Recruiting
NCT05108805Phase 4

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Completed
NCT03189212Not Applicable

Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation

Completed
NCT04652674Not Applicable

Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic

Completed
NCT04503538Not Applicable

Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6